1. Home
  2. RPRX

as 03-28-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Founded: 1996 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 14.2B IPO Year: 2020
Target Price: $41.60 AVG Volume (30 days): 4.2M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
2.81%
Dividend Payout Frequency: Quarterly
EPS: 1.91 EPS Growth: -24.54
52 Week Low/High: $24.05 - $34.20 Next Earning Date: 05-08-2025
Revenue: $2,263,576,000 Revenue Growth: -3.86%
Revenue Growth (this year): 33.46% Revenue Growth (next year): 4.44%

RPRX Daily Stock ML Predictions

Share on Social Networks: